US healthcare company Johnson & Johnson (NYSE: JNJ) on Friday announced the release of two-year Phase 3 results from ICONIC-TOTAL assessing ICOTYDE (icotrokinra) in adults and adolescents with moderate high-impact plaque psoriasis.
The oral peptide, which blocks the IL-23 receptor, was found to deliver sustained skin clearance through to Week 112.
Clear or almost clear skin (Investigator's Global Assessment 0/1) increased from 57% at Week 16 to 70% at Week 112 among treated patients. Site-specific complete clearance at Week 112 reached 60% in scalp psoriasis, 89% in genital psoriasis and 63% in psoriasis affecting the hands and/or feet.
Nail psoriasis also improved, with mean modified Nail Psoriasis Severity Index (mNAPSI) scores rising from 33% at Week 16 to 71% at Week 112. Safety findings remained consistent with the established profile, with no new signals reported.
ICONIC-TOTAL is part of a broader Phase 3 programme evaluating ICOTYDE across plaque psoriasis and related inflammatory conditions, including studies comparing the drug with placebo and deucravacitinib. ICOTYDE is approved in multiple regions for moderate-to-severe plaque psoriasis and is being studied in psoriatic arthritis, ulcerative colitis and Crohn's disease.
Johnson & Johnson reveals new Phase 2 nipocalimab study data in Sjögren's disease
GlycoNex submits marketing authorisation application for denosumab biosimilar to Japanese regulator
Akeso publishes ivonescimab Phase II study results in Nature Medicine
First patient dosed in Phase 1 trial of Transgene and BioInvent's BT-001 for rectal cancer
SK Biopharmaceuticals submits cenobamate supplemental New Drug Application to US FDA
Minghui Pharmaceutical licenses IGF-1R antibody to ASKA Pharmaceutical in Japan